Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.

Thymidylate synthase (TS) converts dUMP to dTMP, the rate-limiting nucleotide in DNA synthesis. It is also the target for 5-flurorouracil, the most common chemotherapy agent for treatment of colorectal cancer (CRC). We designed a nested case-control study within the prospective Physicians' Health Study to investigate whether TS polymorphisms independently predict risk of CRC and simultaneously the overall survival after the disease in the same population. We also investigated influences of this polymorphism on plasma folate and homocysteine levels. The study consists of 270 incident CRC and 454 control subjects. Risk of CRC was estimated by use of conditional multiple logistic regression analysis. Survival was analyzed by Cox proportional hazards regression analysis. Compared with the TS 3R/3R genotype, the multivariate-adjusted risk ratio was 0.86 (0.59-1.25) for the 2R/3R genotype and 0.59 (0.36-0.98) for the 2R/2R genotype with P for trend of 0.03. The TS 2R/2R genotype was also associated with better survival, although the results were not significant. Compared with those with either the 3R/3R or 2R/3R genotypes, the age-adjusted hazard ratio for the 2R/2R genotype was 0.57 (0.30-1.07). Individuals with the 2R/2R genotype had significantly lower plasma folate levels than those with the 3R/3R genotype, whereas their plasma homocysteine levels were unaffected by the TS promoter polymorphism. The deletion polymorphism at the TS 3'-untranslated region did not influence the CRC risk and survival, nor did it modify the plasma folate and total homocysteine levels. Given that individuals with high plasma folate had a better survival outcome with a hazard ratio of 0.68 (0.45-1.03) compared with those with low plasma folate, we conclude that the TS promoter polymorphism may modify both the risk and the survival of CRC; however, these effects do not appear to be mediated through its modulation of biological folate levels.

[1]  L. Jorde,et al.  Length Polymorphism of Thymidylate Synthase Regulatory Region in Chinese Populations and Evolution of the Novel Alleles , 2002, Biochemical Genetics.

[2]  G. Coetzee,et al.  Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels , 2002, Human Genetics.

[3]  C. Ulrich,et al.  Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. , 2002, Cancer research.

[4]  C. Ulrich,et al.  Pharmacogenetics and folate metabolism -- a promising direction. , 2002, Pharmacogenomics.

[5]  B. Iacopetta,et al.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.

[6]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[7]  P. Dennis,et al.  Downregulation of p21/WAF1 expression by thymidylate synthase. , 2001, Biochemical and biophysical research communications.

[8]  H. Blom,et al.  Folate, Homocysteine and Neural Tube Defects: An Overview , 2001, Experimental biology and medicine.

[9]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[11]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  H. McLeod,et al.  Novel thymidylate synthase enhancer region alleles in African populations , 2000, Human mutation.

[13]  S. Ackland,et al.  Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells , 2000, Cancer Chemotherapy and Pharmacology.

[14]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[15]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Riboli,et al.  Serum folate, homocysteine and colorectal cancer risk in women: a nested case–control study , 1999, British Journal of Cancer.

[17]  N. Horie,et al.  Identification of Functional Elements in the Promoter Region of the Human Gene for Thymidylate Synthase and Nuclear Factors That Regulate the Expression of the Gene* , 1997, The Journal of Biological Chemistry.

[18]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. , 1997, Cancer research.

[19]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Wilson,et al.  Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. , 1996, JAMA.

[21]  E. Rimm,et al.  A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. , 1996, Cancer research.

[22]  D. Winchester,et al.  The National Cancer Data Base report on colon cancer , 1996, Cancer.

[23]  G. Aherne,et al.  Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. , 1996, Biochemical pharmacology.

[24]  C. Allegra,et al.  The role of thymidylate synthase as an RNA binding protein , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[26]  P. Johnston,et al.  Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. , 1995, British Journal of Cancer.

[27]  E. Rimm,et al.  Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. , 1995, Journal of the National Cancer Institute.

[28]  C. Moertel.  Chemotherapy for colorectal cancer. , 1994, The New England journal of medicine.

[29]  Jurg Ott,et al.  Handbook of Human Genetic Linkage , 1994 .

[30]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[31]  T. Kunkel,et al.  The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. , 1992, The Journal of biological chemistry.

[32]  A. Harris,et al.  Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. , 1991, Cancer research.

[33]  T. Tamura,et al.  Inhibition of EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. , 1990, Clinical chemistry.

[34]  J. Eble,et al.  Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation. , 1988, Cancer biochemistry biophysics.

[35]  S. Altman,et al.  Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. , 1987, Nucleic acids research.

[36]  Jackson Rc,et al.  Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid (CB3717), on human lymphoblastoid cells , 1983 .

[37]  R. Jackson,et al.  Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells. , 1983, Biochemical pharmacology.